Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

[1]  H. Döhner,et al.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Garcia-Manero,et al.  Hypomethylating agents and other novel strategies in myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Hoelzer,et al.  Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Andreeff,et al.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Béné,et al.  Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Czuczman,et al.  Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma , 2009, Cancer.

[8]  L. Tremmel,et al.  Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Kalaycio.  Bendamustine: a new look at an old drug. , 2009, Cancer.

[11]  A. Tulpule,et al.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Friedberg,et al.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  U. Germing,et al.  A pilot study of bendamustine in elderly patients with high-risk MDS and AML , 2007, Leukemia & lymphoma.

[14]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[15]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[16]  K. Do,et al.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Hansmann,et al.  Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kantarjian,et al.  Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.

[19]  R. Miller,et al.  A new look at an old drug. , 1983, Anesthesiology.